There were 1,473 press releases posted in the last 24 hours and 424,854 in the last 365 days.

Assisted Reproductive Technology ART Market To Reach USD 50.71 Billion By 2026 | Reports And Data

Increase in incidences of infertility coupled with an increasing social acceptance of assisted reproductive technology globally, are the major factors influencing market growth.

Market Size – USD 23.64 billion in 2018, Market Growth - CAGR of 9.9 %, Market Trends –Technological advancement along with increasing incidences of infertility

NEW YORK, May 14, 2019 (GLOBE NEWSWIRE) -- The Assisted Reproductive Technology (ART) Market is expected to reach USD 50.71 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with the continuous growth in infertility rate, increasing knowledge and acceptance of assisted reproductive technologies socially which are expected to further accelerate the market growth globally. Based on statistics, rise in ovulation disorders, increasing unhealthy eating habits which in turn result in obesity are also some of the factors that help to grow the size of the global market.

Request free sample of this research report at:

Assisted reproductive technology (ART) is the treatment for fertility in which eggs are separated surgically from the women ovaries and are mixed with male sperms in the laboratory. Further, they are either passed to the ovaries or are donated to another woman. ART does not involve the treatment where only sperms are handled, or pills are taken to spur egg production. ART can be used to bypass fertility problems while conserving the genetic connection. The world’s first test tube baby was born in Britain in 1978, and by 2012, around 1.5 million ART cycles were conducted worldwide annually. Nevertheless, almost 76.7% of ART procedures failed, and about 23.3% were successful. Generally, ART is suggested when other methods have not been successful and when there is a condition of male infertility or tubal blocking.

APAC is forecasted to be the fastest growing market with the highest rate of 10.0% during the forecast period. The drivers for the growth of this region are, delayed family planning and relatively lower treatment value. ASPIRE (APAC Initiative on Reproduction), held on 4th April 2014, to guide the healthcare professionals on how to help the patients on several infertility treatments and to enhance the quality of patient care.

Further key findings from the report suggest

  • The increasing number of infertility cases across the world is a significant factor propelling the growth of the market.

  • The growing incidences of infertility and increase in acceptance of ART socially are some of the other important factors responsible for the market growth globally.

  • The demand for ART technologies like artificial insemination (AI) and in-vitro fertilization (IVF) is increasing due to the factors associated with the various incidences of infertility.

  • Growing population and rising healthcare expenditure are the fundamental factors which are boosting the growth of the market across the globe.

  • Frozen Embryo Replacement (FER) technology is anticipated to grow at the highest rate of 10.0% during the forecast period.

To identify the key trends in the industry, click on the link below:

  • Innovative product development and collaborative developments are some of the critical strategic initiatives taken by the players in this industry to point their mark in the competition.

  • Frozen non-donor of the procedure segment is expected to grow at the highest rate of 10.0% during the forecast period.

  • This method has an advantage over fresh approach as it is less costly and the recipient does not have to go through the drug stimulation process and is less invasive.

  • Many compensation policies have also inspired more people to donate or store their gametes.

  • Also, Medical Egg Freezing (MEF) is prescribed for women at risk of losing fertility due to cancer treatment and other fertility-threatening diseases.

  • Other region such as the APAC is anticipated to grow at the highest rate of 10.0% during the forecast period.

  • The increase in this region is due to the rising population, and the emerging healthcare network which are expected to spur the market in the future.

  • Europe accounts for a share of 29.2% in 2018 and is expected to grow at a rate of 9.9 % during the forecast period.

  • Key participants include Bloom IVF Centre, California Cryobank, Parallabs, Anecova, OvaScience, Origio, Merck KGaA, Microm Ltd., Cooper Surgical, Inc, Irvine Scientific and Hamilton Throne Ltd., Ferring Pharmaceuticals

Order Now:

Segments covered in the report:

For the purpose of this study, Reports and Data have segmented the global Assisted Reproductive Technology (ART) Market on the basis of Procedure, Technology, End-User, Type and Region:                      

Procedure Outlook (Revenue, USD Million; 2016-2026)

  • Fresh Non donor

  • Fresh Donor

  • Frozen Donor

  • Frozen Non donor

  • Embryo/Egg Banking

End User Outlook (Revenue, USD Million; 2016-2026)

  • Fertility Clinics

  • IVF Center

  • Hospital

Technology Outlook (Revenue, USD Million; 2016-2026)

  • IVF

  • FER

  • IVF with ICSI

  • IVF without ICSI

  • Others

Type Outlook (Revenue, USD Million; 2016-2026)

  • Artificial Insemination

  • Ovulation Induction

  • Surrogacy

Regional Outlook (Revenue, USD Million; 2016-2026)

  • North America

    • U.S.

  • Europe

    • UK

    • France

  • Asia Pacific

    • China

    • India

    • Japan

  • MEA

  • Latin America

    • Brazil

Browse more reports of Pharmaceutical category at:

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John Watson

Head of Business Development

Reports And Data | Web:

Direct Line: +1-800-819-3052


RND logo.PNG